The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

BACKGROUND: People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Nephrol
Main Authors: Jardine, Meg J., Mahaffey, Kenneth W., Neal, Bruce, Agarwal, Rajiv, Bakris, George L., Brenner, Barry M., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Pollock, Carol, Wheeler, David C., Xie, John, Zhang, Hong, Zinman, Bernard, Desai, Mehul, Perkovic, Vlado
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2018
Assuntos:
Original Report: Patient-Oriented, Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5804835/
https://ncbi.nlm.nih.gov/pubmed/29253846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000484633
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados